• OPEN AN ACCOUNT
Indian Indices
Nifty
17,617.15 -139.85
(-0.79%)
Sensex
59,037.18 -427.44
( -0.72%)
Bank Nifty
37,574.30 -276.55
( -0.73%)
Nifty IT
36,054.55 -607.65
( -1.66%)
Global Indices
Nasdaq
13,768.92 -385.10
(-2.72%)
Dow Jones
34,265.37 -450.02
(-1.30%)
Hang Seng
24,965.55 13.20
(0.05%)
Nikkei 225
27,522.26 -250.67
(-0.90%)
Forex
USD-INR
74.31 0.00
(0.00%)
EUR-INR
84.22 -0.03
(-0.03%)
GBP-INR
100.83 -0.38
(-0.38%)
JPY-INR
0.65 0.00
(0.41%)

EQUITY - MARKET SCREENER

Exide Industries Ltd
Industry :  Auto Ancillaries
BSE Code
ISIN Demat
Book Value()
500086
INE302A01020
85.4951765
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EXIDEIND
17.69
14960
EPS(TTM)
Face Value()
Div & Yield %
9.95
1
1.14
 

Cipla Ltd
Cipla receives USFDA final approval for Lanreotide Injection
Dec 20,2021
Cipla announced that it has received final approval for its Lanreotide Injection, from the United States Food and Drug Administration (US FDA). The FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.

Lanreotide Injection is supplied in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL singledose pre-filled syringes. It is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).

The active ingredient, route of administration and strengths are the same as SOMATULINE DEPOT®, from Ipsen Biopharmaceuticals Inc. According to IQVIA, SOMATULINE DEPOT® had US sales of approximately $867M for the 12-month period ending October 2021.